Tiziana Life Sciences Pitch Deck Teardown: A Multi-Asset

Slide-by-Slide Analysis

Slide 1: Title Slide

The title slide establishes Tiziana Life Sciences as a platform company. It clearly states the focus: "An Innovative Platform in Oral, Nasal and Inhalation for Monoclonal Antibody Administration." The slide lists specific target indications including Crohn’s Disease, COVID-19, Autoimmune Disease, and Hepatocellular Carcinoma. It also prominently displays the company's tickers on the NASDAQ (TLSA) and AIM (TILS), signaling its status as a publicly traded entity. The date, April 2020, provides essential context for the inclusion of COVID-19 in the pipeline.

Slide 4: Scientific Advisory Committee

This slide is a high-impact credibility builder. In biotech, the pedigree of the advisors often dictates investor confidence. Tiziana lists six MDs with affiliations to Harvard, Yale, and the University of Milan. Most notable is Napoleone Ferrara, MD, identified as the inventor of Avastin, a drug with stated revenues of $6.67 billion per year. The inclusion of a Lasker Award winner and leaders in mucosal immunology (Howard Weiner) and liver disease (Arun Sanyal) suggests a deep bench of expertise supporting their diverse clinical programs.

Slide 7: Development Pipeline

The pipeline slide is the core of any biotech deck. Tiziana shows three distinct assets: Foralumab, TZLS-501, and Milciclib. Foralumab is shown in three tracks: intranasal for neurodegeneration (starting Phase 2), enteric-coated capsules for Crohn's/NASH (starting Phase 2), and an I.V. formulation for Crohn's. TZLS-501 is positioned for COVID-19 with clinical studies "to begin shortly." Milciclib is the most advanced, with a Phase 2a completed for HCC oral monotherapy. The visual layout clearly distinguishes between discovery, pre-clinical, and clinical phases, showing a company with multiple shots on goal.

Slide 10: Oral and Nasal Formulation Patents Pending

This slide focuses on the defensibility of their delivery platform. It highlights that proof-of-concept has been demonstrated in animal studies and that a Phase 1 study at Brigham and Women’s Hospital was well-tolerated up to 250 micrograms. The slide lists specific patent application numbers (e.g., US 62/380,652) and emphasizes an "exclusive license for composition of matter." By targeting Pro-MS, Alzheimer’s, Crohn’s, and NASH, the company demonstrates the versatility of their IP estate.

Slide 13: Clinical Validation for Oral Administration

Tiziana uses this slide to provide external validation for their approach. It cites a study conducted by Dr. Scott Snapper at Harvard Medical School involving oral anti-CD3 (OKT3) in patients with ulcerative colitis. The key findings are quantified: 3 of 6 patients had a clinical response, and the treatment was well-tolerated. While the sample size is small (six subjects), it serves as a biological proof-of-concept for the company's larger Foralumab trials.

Slide 16: Therapeutic Options for COVID-19

Reflecting the timing of the presentation (April 2020), this slide addresses the urgent global need for COVID-19 treatments. It uses a time-course graph to show the progression from viral infection to "Cytokine Storm" and death. Tiziana positions their anti-inflammatory treatment as a way to interrupt this progression. The slide argues that a combination of anti-viral and anti-inflammatory drugs is the optimal therapeutic path, placing their TZLS-501 asset in the latter category.

Slide 19: Clinical Data from Milciclib

This slide provides granular data on their oncology asset. It details a Phase 2a trial in sorafenib-resistant HCC patients. Key metrics include: 28 out of 31 evaluable patients, no drug-related deaths, and a "Clinical Benefit Response" of 64%. The slide also mentions that two patients continued treatment under compassionate use for 18 months, which is a powerful anecdotal data point for efficacy in a difficult-to-treat patient population.

Slide 22: Intellectual Property Portfolio

The IP portfolio slide is a comprehensive table listing the family, subject, priority date, status, and jurisdiction of their patents. It shows that their protections are global, covering the US, EU, China, Japan, and several other regions. Crucially, it lists expiration dates ranging from 2024 to 2039. This level of detail is intended to reassure institutional investors that the company has a long runway of market exclusivity for its primary assets.

Slide 27: Contact Us

The final slide provides contact information for their US Headquarters in New York, their R&D Center in Doylestown, PA, and their UK Headquarters in London. It includes direct email addresses for investor relations and the company website. The dual-listing tickers (TLSA and TILS) are repeated, reinforcing the company's public market presence.

What Tiziana Life Sciences Does Well

Tiziana excels at institutional signaling . By leading with a Scientific Advisory Board full of world-renowned researchers and inventors of blockbuster drugs, they immediately overcome the skepticism often directed at small-cap biotech firms. The deck is also highly effective at visualizing the pipeline . The use of clear horizontal bars to show the progression of multiple assets across different delivery methods allows an investor to quickly grasp the breadth of the company's strategy.

Furthermore, the company does a thorough job of documenting its IP . In the life sciences sector, the patent is the product. By listing specific application numbers and expiration dates that extend nearly two decades into the future, Tiziana provides a clear picture of its long-term value proposition. The inclusion of specific clinical data points (e.g., 64% clinical benefit response on Slide 19) adds a layer of quantitative evidence that balances the more theoretical platform descriptions.

What is Missing from the Deck

As a corporate presentation for a public company, this deck is designed for a specific audience, but it leaves several gaps that a private investor or a new shareholder might find frustrating. First, there is no financial summary . There is no mention of cash on hand, burn rate, or how long the current capital will last. For a company with multiple Phase 2 trials starting, the capital requirements are enormous, and the omission of financial health is a significant gap.

Second, the deck lacks a competitive landscape analysis . While they mention Avastin in the context of their advisor, they do not show how Foralumab or Milciclib compare to other drugs currently in the clinic or on the market for Crohn's, NASH, or HCC. Finally, there is no management team slide in the provided selection. While the scientific advisors are top-tier, the executives responsible for the day-to-day operations and capital allocation are not introduced, which is a standard requirement for assessing execution risk.

Instructions for Founders

Founders in the biotech space should look to Tiziana’s Scientific Advisory Board slide (Slide 4) as a gold standard. If you have high-profile advisors, do not just list their names; list their specific achievements, the dollar value of the drugs they have invented, and their institutional affiliations. This creates an immediate "halo effect" for your company.

Additionally, the IP Portfolio slide (Slide 22) is a model of transparency. Instead of saying "we have a strong patent position," Tiziana shows the table. Founders should be prepared to provide this level of detail to serious investors, as it proves the company has done the legal legwork to protect its innovations. Lastly, the Pipeline slide (Slide 7) is an excellent example of how to show a platform's versatility without making the slide look cluttered. Using color-coded bars and clear labels for delivery methods (nasal vs. oral) helps investors understand the "platform" aspect of the business rather than just seeing a list of unrelated drugs.